Giacomo Carteni
Modena, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
Journal: ESMO open
Published: July 28, 2022
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.
Journal: Cancers
Published: March 20, 2022
The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target.
Journal: Journal of oncology
Published: October 04, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.
Journal: World journal of clinical oncology
Published: February 27, 2021
Second-line treatment in renal cell carcinoma: clinical experience and decision making.
Journal: Therapeutic advances in urology
Published: January 12, 2021
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Journal: Diagnostics (Basel, Switzerland)
Published: December 22, 2020
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Journal: Journal for immunotherapy of cancer
Published: August 08, 2020
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Journal: Japanese journal of clinical oncology
Published: June 24, 2020
ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-zeolite to prevent Chemotherapy-Induced Side Effects, in particular, Peripheral Neuropathy.
Journal: Molecules (Basel, Switzerland)
Published: March 23, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Journal: Cancers
Published: October 01, 2019
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 12, 2019
Last Updated: 09/26/2026